# Vivos Therapeutics, Inc.: financial statements, quarterly

VVOS · Nasdaq · CIK 1716166 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vvos.md) · [Financials](/companies/vvos/financials.md) · [Filings](/companies/vvos/filings.md) · [Insiders](/companies/vvos/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vvos/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [3,301](/filings/0001493152-24-045888.md) | [3,248 d](/filings/0001641172-25-001750.md) | [3,419](/filings/0001641172-25-010874.md) | [4,054](/filings/0001641172-25-024832.md) | [3,860](/filings/0001493152-25-024253.md) | [3,698 d](/filings/0001493152-26-016854.md) | [3,016](/filings/0001493152-26-024650.md) | [3,820](/filings/0001493152-26-038336.md) | [6,783](/filings/0001493152-25-024253.md) | [3,824 d](/filings/0001493152-26-016854.md) | [5,141](/filings/0001493152-26-024650.md) | [5,153](/filings/0001493152-26-038336.md) |
| Cost of revenue | $k | [100](/filings/0001493152-23-041150.md) | [5,330 d](/filings/0001641172-25-001750.md) | [100](/filings/0001493152-24-019247.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $k | [1,747](/filings/0001493152-24-045888.md) | [2,089 d](/filings/0001641172-25-001750.md) | [1,937](/filings/0001641172-25-010874.md) | [2,651](/filings/0001641172-25-024832.md) | [2,334](/filings/0001493152-25-024253.md) | [2,097 d](/filings/0001493152-26-016854.md) | [1,509](/filings/0001493152-26-024650.md) | [2,110](/filings/0001493152-26-038336.md) | [3,937](/filings/0001493152-25-024253.md) | [2,988 d](/filings/0001493152-26-016854.md) | [3,059](/filings/0001493152-26-024650.md) | [2,953](/filings/0001493152-26-038336.md) |
| Research and development | $k | [100](/filings/0001493152-23-041150.md) | [(100) d](/filings/0001641172-25-001750.md) | [100](/filings/0001493152-24-019247.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $k | [(3,640)](/filings/0001493152-24-045888.md) | [(4,133) d](/filings/0001641172-25-001750.md) | [(3,785)](/filings/0001641172-25-010874.md) | [(1,936)](/filings/0001641172-25-024832.md) | [(2,645)](/filings/0001493152-25-024253.md) | [(2,806) d](/filings/0001493152-26-016854.md) | [(3,918)](/filings/0001493152-26-024650.md) | [(4,865)](/filings/0001493152-26-038336.md) | [(4,734)](/filings/0001493152-25-024253.md) | [(6,382) d](/filings/0001493152-26-016854.md) | [(6,615)](/filings/0001493152-26-024650.md) | [(4,825)](/filings/0001493152-26-038336.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [500](/filings/0001493152-25-024253.md) | [800 d](/filings/0001493152-26-016854.md) | [1,100](/filings/0001493152-26-024650.md) | [1,100](/filings/0001493152-26-038336.md) |
| Net income | $k | [(2,093)](/filings/0001493152-24-045888.md) | [(4,259) d](/filings/0001641172-25-001750.md) | [(3,763)](/filings/0001493152-25-024253.md) | [(1,930)](/filings/0001493152-25-024253.md) | [(2,616)](/filings/0001493152-25-024253.md) | [(2,827) d](/filings/0001493152-26-016854.md) | [(3,864)](/filings/0001493152-26-024650.md) | [(5,013)](/filings/0001493152-26-038336.md) | [(5,400)](/filings/0001493152-25-024253.md) | [(6,894) d](/filings/0001493152-26-016854.md) | [(7,682)](/filings/0001493152-26-024650.md) | [(5,481)](/filings/0001493152-26-038336.md) |
| Diluted EPS | $ per share | [(1.75)](/filings/0001493152-24-045888.md) | not reported | [(1.63)](/filings/0001641172-25-010874.md) | [(0.60)](/filings/0001641172-25-024832.md) | [(0.40)](/filings/0001493152-25-024253.md) | not reported | [(0.45)](/filings/0001493152-26-024650.md) | [(0.55)](/filings/0001493152-26-038336.md) | [(0.49)](/filings/0001493152-25-024253.md) | not reported | [(0.52)](/filings/0001493152-26-024650.md) | [(0.31)](/filings/0001493152-26-038336.md) |
| Basic EPS | $ per share | [(1.75)](/filings/0001493152-24-045888.md) | not reported | [(1.63)](/filings/0001641172-25-010874.md) | [(0.60)](/filings/0001641172-25-024832.md) | [(0.40)](/filings/0001493152-25-024253.md) | not reported | [(0.45)](/filings/0001493152-26-024650.md) | [(0.55)](/filings/0001493152-26-038336.md) | [(0.49)](/filings/0001493152-25-024253.md) | not reported | [(0.52)](/filings/0001493152-26-024650.md) | [(0.31)](/filings/0001493152-26-038336.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold, us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | period not labelled (2025-06-10) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1.6](/filings/0001641172-25-001750.md) | [2.6](/filings/0001493152-24-019247.md) | [6.9](/filings/0001493152-24-032240.md) | [6.3](/filings/0001493152-24-045888.md) | [6.3](/filings/0001493152-26-016854.md) | [2.3](/filings/0001641172-25-010874.md) | [6.0](/filings/0001641172-25-024832.md) | [4.4](/filings/0001641172-25-024832.md) | [3.1](/filings/0001493152-25-024253.md) | [2.0](/filings/0001493152-26-038336.md) | [2.1](/filings/0001493152-26-024650.md) | [1.8](/filings/0001493152-26-038336.md) |
| Current assets | $m | [2.5](/filings/0001641172-25-001750.md) | [3.6](/filings/0001493152-24-019247.md) | [7.9](/filings/0001493152-24-032240.md) | [7.4](/filings/0001493152-24-045888.md) | [7.5](/filings/0001493152-26-016854.md) | [3.6](/filings/0001641172-25-010874.md) | not reported | [6.7](/filings/0001641172-25-024832.md) | [5.8](/filings/0001493152-25-024253.md) | [4.4](/filings/0001493152-26-038336.md) | [4.8](/filings/0001493152-26-024650.md) | [4.2](/filings/0001493152-26-038336.md) |
| Total assets | $m | [10.7](/filings/0001641172-25-001750.md) | [11.8](/filings/0001493152-24-019247.md) | [15.8](/filings/0001493152-24-032240.md) | [15.3](/filings/0001493152-24-045888.md) | [15.3](/filings/0001493152-26-016854.md) | [11.3](/filings/0001641172-25-010874.md) | not reported | [26.0](/filings/0001641172-25-024832.md) | [25.6](/filings/0001493152-25-024253.md) | [25.2](/filings/0001493152-26-038336.md) | [25.0](/filings/0001493152-26-024650.md) | [24.1](/filings/0001493152-26-038336.md) |
| Current liabilities | $m | [7.3](/filings/0001641172-25-001750.md) | [8.1](/filings/0001493152-24-019247.md) | [6.6](/filings/0001493152-24-032240.md) | [5.1](/filings/0001493152-24-045888.md) | [5.0](/filings/0001493152-26-016854.md) | [4.7](/filings/0001641172-25-010874.md) | not reported | [6.4](/filings/0001641172-25-024832.md) | [7.4](/filings/0001493152-25-024253.md) | [18.1](/filings/0001493152-26-038336.md) | [17.9](/filings/0001493152-26-024650.md) | [20.4](/filings/0001493152-26-038336.md) |
| Total liabilities | $m | [10.3](/filings/0001641172-25-001750.md) | [11.2](/filings/0001493152-24-019247.md) | [9.5](/filings/0001493152-24-032240.md) | [7.7](/filings/0001493152-24-045888.md) | [7.3](/filings/0001493152-26-016854.md) | [6.9](/filings/0001641172-25-010874.md) | not reported | [21.5](/filings/0001641172-25-024832.md) | [23.1](/filings/0001493152-25-024253.md) | [26.7](/filings/0001493152-26-038336.md) | [26.3](/filings/0001493152-26-024650.md) | [28.1](/filings/0001493152-26-038336.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [7.8](/filings/0001641172-25-024832.md) | [8.4](/filings/0001493152-25-024253.md) | [0.5](/filings/0001493152-26-038336.md) | [0.4](/filings/0001493152-26-024650.md) | [0.4](/filings/0001493152-26-038336.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.2](/filings/0001641172-25-024832.md) | [0.3](/filings/0001493152-25-024253.md) | [8.4](/filings/0001493152-26-038336.md) | [7.3](/filings/0001493152-26-024650.md) | [7.8](/filings/0001493152-26-038336.md) |
| Shareholders' equity | $m | [0.4](/filings/0001493152-25-024253.md) | [0.6](/filings/0001493152-25-024253.md) | [6.3](/filings/0001493152-25-024253.md) | [7.7](/filings/0001493152-25-024253.md) | [8.0](/filings/0001493152-26-016854.md) | [4.4](/filings/0001493152-25-024253.md) | not reported | [4.6](/filings/0001493152-25-024253.md) | [2.5](/filings/0001493152-25-024253.md) | [(1.5)](/filings/0001493152-26-038336.md) | [(1.1)](/filings/0001493152-26-024650.md) | [(3.8)](/filings/0001493152-26-038336.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,800) d](/filings/0001493152-24-045888.md) | [(2,748) d](/filings/0001641172-25-001750.md) | [(2,516)](/filings/0001641172-25-010874.md) | [(3,048) d](/filings/0001641172-25-024832.md) | [(4,187) d](/filings/0001493152-25-024253.md) | [(2,940) d](/filings/0001493152-26-016854.md) | [(3,796)](/filings/0001493152-26-024650.md) | [(3,494) d](/filings/0001493152-26-038336.md) | [(4,161) d](/filings/0001493152-25-024253.md) | [(3,812) d](/filings/0001493152-26-016854.md) | [(6,010)](/filings/0001493152-26-024650.md) | [(3,148) d](/filings/0001493152-26-038336.md) |
| Capital expenditure | $k | [154 d](/filings/0001493152-24-045888.md) | [165 d](/filings/0001641172-25-001750.md) | [151](/filings/0001641172-25-010874.md) | [60.0 d](/filings/0001641172-25-024832.md) | [192 d](/filings/0001493152-25-024253.md) | [165 d](/filings/0001493152-26-016854.md) | [122](/filings/0001493152-26-024650.md) | [771 d](/filings/0001493152-26-038336.md) | [(83.0) d](/filings/0001493152-25-024253.md) | [1,531 d](/filings/0001493152-26-016854.md) | [18.0](/filings/0001493152-26-024650.md) | [416 d](/filings/0001493152-26-038336.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.8](/filings/0001493152-23-041150.md) | [1.0](/filings/0001493152-24-019247.md) | [1.2](/filings/0001493152-24-032240.md) | [1.2](/filings/0001493152-24-045888.md) | [2.3](/filings/0001641172-25-010874.md) | [3.2](/filings/0001641172-25-024832.md) | [6.6](/filings/0001493152-25-024253.md) | [8.6](/filings/0001493152-26-024650.md) | [9.1](/filings/0001493152-26-038336.md) | [11.0](/filings/0001493152-25-024253.md) | [14.6](/filings/0001493152-26-024650.md) | [17.7](/filings/0001493152-26-038336.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 20,118,023 at 2026-08-13, from the cover of the [10-Q filed 2026-08-14](/filings/0001493152-26-038336.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.